United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $586.75, for a total value of $4,870,025.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $26,504,671. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $569.18 on Friday. The business’s 50 day moving average price is $550.17 and its 200-day moving average price is $501.37. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The company has a market cap of $24.05 billion, a P/E ratio of 21.01, a P/E/G ratio of 1.70 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.63 earnings per share. As a group, equities analysts predict that United Therapeutics Corporation will post 27.97 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Bank of America upped their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. TD Cowen increased their price target on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Wells Fargo & Company set a $735.00 price target on United Therapeutics and gave the stock an “overweight” rating in a research note on Thursday. Finally, Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors focused on product/catalyst upside — market reaction was supported by management highlighting positive Tyvaso data in IPF and continued optimism around ralinepag’s blockbuster potential, which many say could drive significant future growth. UTHR Q1 Earnings Miss — Shares Jump on Strong Outlook
• Positive Sentiment: Partnership expansion with MannKind around DPI technology may improve delivery/manufacturing optionality and was reported to boost MannKind’s stock — a potential operational positive for United Therapeutics’ inhaled product ambitions. MannKind Stock Surges on Partnership
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $707 to $701 but retained an “outperform” rating, leaving a sizable implied upside from current levels; this is broadly supportive but not catalytic. RBC Lowers PT to $701
• Negative Sentiment: Q1 financials missed consensus: EPS of $5.82 vs. estimates near $7.00 and revenue $781.5M vs. ~$797M — revenue declined ~2% YoY. The miss can pressure short-term sentiment despite healthy margins. Q1 2026 Financial Results
• Negative Sentiment: Significant insider selling: CEO Martine Rothblatt sold 9,500 shares (~19% reduction in her disclosed holding) and EVP Paul Mahon sold 8,300 shares (~15.5% reduction). Large, contemporaneous insider reductions can weigh on sentiment, especially after an earnings miss. Rothblatt SEC Filing Mahon SEC Filing

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC bought a new stake in United Therapeutics during the 4th quarter valued at $31,000. International Assets Investment Management LLC lifted its holdings in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.